Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunome Inc (IMNM)

Immunome Inc (IMNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,794,765
  • Shares Outstanding, K 91,710
  • Annual Sales, $ 9,040 K
  • Annual Income, $ -292,960 K
  • EBIT $ -225 M
  • EBITDA $ -225 M
  • 60-Month Beta 2.17
  • Price/Sales 197.70
  • Price/Cash Flow N/A
  • Price/Book 6.43

Options Overview Details

View History
  • Implied Volatility 105.96% (-125.61%)
  • Historical Volatility 92.21%
  • IV Percentile 18%
  • IV Rank 13.84%
  • IV High 298.95% on 09/19/25
  • IV Low 74.94% on 12/18/24
  • Expected Move (DTE 4) 2.34 (9.85%)
  • Put/Call Vol Ratio 0.39
  • Today's Volume 6,216
  • Volume Avg (30-Day) 941
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 19,757
  • Open Int (30-Day) 18,082
  • Expected Range 21.39 to 26.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 6
  • High Estimate -0.58
  • Low Estimate -0.75
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +22.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.81 +43.37%
on 12/02/25
25.30 -4.74%
on 12/15/25
+6.96 (+40.61%)
since 11/14/25
3-Month
8.93 +170.03%
on 09/17/25
25.30 -4.74%
on 12/15/25
+14.62 (+154.22%)
since 09/15/25
52-Week
5.15 +367.96%
on 04/09/25
25.30 -4.74%
on 12/15/25
+11.52 (+91.57%)
since 12/13/24

Most Recent Stories

More News
Stocks Turn Lower on AI Spending Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.26%. December E-mini...

MSTR : 164.11 (-6.99%)
AMAT : 262.14 (+1.13%)
IMNM : 23.39 (+19.52%)
GLXY : 24.73 (-7.55%)
BLDR : 105.04 (-3.17%)
AKAM : 87.44 (+1.82%)
$IUXX : 25,096.11 (-0.40%)
COIN : 250.70 (-6.27%)
ZNH26 : 112-085 (+0.08%)
OXY : 40.03 (-2.53%)
ESZ25 : 6,818.75 (-0.18%)
FANG : 153.70 (-1.90%)
Stocks Climb in Anticipation of Fed-Friendly US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.50%. December E-mini S&P futures...

TER : 195.00 (+0.84%)
AMAT : 262.14 (+1.13%)
IMNM : 23.39 (+19.52%)
B : 43.35 (+0.60%)
HL : 19.15 (+1.81%)
AKAM : 87.44 (+1.82%)
TXN : 178.58 (-0.47%)
$IUXX : 25,096.11 (-0.40%)
ASML : 1,086.99 (+0.57%)
ZNH26 : 112-085 (+0.08%)
ESZ25 : 6,818.75 (-0.18%)
LYB : 43.34 (-2.37%)
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p

IMNM : 23.39 (+19.52%)
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET

IMNM : 23.39 (+19.52%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the...

IMNM : 23.39 (+19.52%)
Immunome to Present at Upcoming Investor Conferences

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s management...

IMNM : 23.39 (+19.52%)
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September...

IMNM : 23.39 (+19.52%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation...

IMNM : 23.39 (+19.52%)
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 2nd...

IMNM : 23.39 (+19.52%)
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary antibody-drug...

IMNM : 23.39 (+19.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

See More

Key Turning Points

3rd Resistance Point 21.00
2nd Resistance Point 20.41
1st Resistance Point 19.99
Last Price 23.39
1st Support Level 18.98
2nd Support Level 18.39
3rd Support Level 17.97

See More

52-Week High 25.30
Last Price 23.39
Fibonacci 61.8% 17.60
Fibonacci 50% 15.22
Fibonacci 38.2% 12.85
52-Week Low 5.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar